Shares of ASLAN PHARMACEU/ADR (NASDAQ:ASLN) have been given an average broker rating score of 1.67 (Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation and two have issued a strong buy recommendation on the company.
Brokerages have set a 1 year consensus price objective of $4.67 for the company and are expecting that the company will post ($0.16) earnings per share for the current quarter, according to Zacks. Zacks has also given ASLAN PHARMACEU/ADR an industry rank of 58 out of 255 based on the ratings given to its competitors.
Several equities analysts have recently issued reports on ASLN shares. Zacks Investment Research raised shares of ASLAN PHARMACEU/ADR from a “hold” rating to a “strong-buy” rating and set a $2.00 price objective on the stock in a research note on Monday, November 4th. Piper Jaffray Companies raised shares of ASLAN PHARMACEU/ADR from a “neutral” rating to an “overweight” rating and set a $8.00 target price for the company in a research note on Monday, December 2nd. BTIG Research cut shares of ASLAN PHARMACEU/ADR from a “buy” rating to a “neutral” rating in a report on Monday, November 11th. Finally, HC Wainwright restated a “buy” rating and issued a $2.00 price target on shares of ASLAN PHARMACEU/ADR in a research report on Monday, November 25th.
A hedge fund recently raised its stake in ASLAN PHARMACEU/ADR stock. FNY Investment Advisers LLC grew its stake in shares of ASLAN PHARMACEU/ADR (NASDAQ:ASLN) by 57.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,100 shares of the company’s stock after purchasing an additional 6,993 shares during the period. FNY Investment Advisers LLC owned about 0.06% of ASLAN PHARMACEU/ADR worth $33,000 as of its most recent SEC filing. Institutional investors own 7.12% of the company’s stock.
NASDAQ:ASLN traded down $0.13 during mid-day trading on Friday, reaching $2.36. 1,530,615 shares of the stock were exchanged, compared to its average volume of 336,903. The company has a current ratio of 1.88, a quick ratio of 3.80 and a debt-to-equity ratio of 1.12. The business has a fifty day moving average price of $1.75 and a 200 day moving average price of $2.46. ASLAN PHARMACEU/ADR has a 1-year low of $0.35 and a 1-year high of $8.18. The firm has a market capitalization of $75.64 million, a PE ratio of -1.69 and a beta of 3.31.
ASLAN PHARMACEU/ADR (NASDAQ:ASLN) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.03) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.19. On average, sell-side analysts forecast that ASLAN PHARMACEU/ADR will post -0.69 earnings per share for the current year.
ASLAN PHARMACEU/ADR Company Profile
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4.
Featured Story: Capital Gains Distribution
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ASLAN PHARMACEU/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEU/ADR and related companies with MarketBeat.com's FREE daily email newsletter.